Jazz Pharmaceuticals (NASDAQ:JAZZ) Updates FY 2025 Earnings Guidance

Key Points

• Jazz Pharmaceuticals has updated its FY 2025 earnings guidance, projecting earnings per share between $4.800 and $5.600, slightly above the consensus estimate of $4.943.
• The company anticipates revenue of $4.2 billion to $4.3 billion, matching the consensus revenue estimate of $4.2 billion.
• Despite recent analyst downgrades, Jazz Pharmaceuticals maintains a consensus rating of "Moderate Buy" with an average price target of $181.64.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 4.800-5.600 for the period, compared to the consensus earnings per share estimate of 4.943. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.2 billion.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating for the company in a report on Tuesday, July 22nd. Piper Sandler reiterated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Finally, Royal Bank Of Canada cut their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $181.64.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded down $2.90 during mid-day trading on Tuesday, reaching $113.20. 1,261,613 shares of the company traded hands, compared to its average volume of 956,511. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. The firm has a market cap of $6.85 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 5.56 and a beta of 0.34. The stock has a fifty day simple moving average of $111.08 and a 200-day simple moving average of $117.78.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($9.07) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($3.46). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. Equities research analysts anticipate that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Seamus Mulligan acquired 100,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the purchase, the director owned 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of JAZZ. Royal Bank of Canada lifted its stake in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company's stock valued at $8,394,000 after purchasing an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock worth $43,652,000 after acquiring an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company's stock worth $24,479,000 after acquiring an additional 7,954 shares during the last quarter. Focus Partners Wealth lifted its position in Jazz Pharmaceuticals by 3.4% during the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company's stock worth $574,000 after acquiring an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 137 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.